Here is how Techne performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: View all Key Company Metrics for Techne here>>> Shares of Techne have returned +3.7% over the past month versus the Zacks S&P 500 composite's +0.5% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term. Organic Growth: 3% versus the three-analyst average estimate of 3%. Organic Growth - Diagn ...

Core Insights - Techne (TECH) reported revenue of $316.18 million for the quarter ended March 2025, reflecting a year-over-year increase of 4.2% and surpassing the Zacks Consensus Estimate by 0.30% [1] - The company's EPS was $0.56, up from $0.48 in the same quarter last year, resulting in an EPS surprise of 9.80% compared to the consensus estimate of $0.51 [1] Financial Performance - Organic Growth was reported at 6%, exceeding the average estimate of 5.2% from three analysts [4] - Organic Growth in Diagnostics and Genomics was 2%, below the two-analyst average estimate of 6.2% [4] - Organic Growth in Protein Sciences was 7%, significantly higher than the average estimate of 2.8% from two analysts [4] - Net Sales from intersegment revenue was -$0.74 million, worse than the average estimate of -$0.55 million, representing a year-over-year decline of 3.7% [4] - Net Sales in Protein Sciences reached $227.69 million, surpassing the average estimate of $224.75 million, with a year-over-year increase of 6.1% [4] - Net Sales in Diagnostics and Genomics were $89.23 million, slightly below the average estimate of $92.50 million, showing a year-over-year growth of 2% [4] Market Performance - Techne's shares have returned -2.2% over the past month, contrasting with the Zacks S&P 500 composite's increase of 10.6% [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the broader market in the near term [3]